The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis

Basit Öğe Kaydı
dc.contributor.authorColpan, L
dc.contributor.authorGur, A
dc.contributor.authorCevik, R
dc.contributor.authorNas, K
dc.contributor.authorSarac, AJ
dc.date.accessioned2024-04-24T16:15:26Z
dc.date.available2024-04-24T16:15:26Z
dc.date.issued2005
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: A double-blind randomized, placebo-controlled trial was conducted in women with postmenopausal osteoporosis to evaluate effects on biochemical markers and urinary excretion of zinc (Zn) of calcitonin therapy. Methods: Patients were required to have a bone mineral density (BMD) of 2.5 S.D. or more below the young adult mean either at the postero-anterior lumbar spine or at the femoral neck. Subjects were eligible for our study if they were 50 years or older, with at least 5 years of menopause, and in good general health as determined by medical history and a routine clinical blood analysis. The patients were randomly assigned to receive intranasal salmon calcitonin (200 IU/day; 50 patients) or placebo (50 patients). All patients received supplemental calcium (1000 mg/day). Additionally, 40 age-matched, demographically similar, healthy postmenopausal women were also selected as controls. Measurements of cross-linked N-telopeptides of type I collagen (uNTx), osteocalcin (sOQ, and urinary zinc concentration were done. All parameters were measured before therapy and again after 1, 3 and 6 months. Results: After 3 and 6 months of treatment, a higher decrease of most indices was observed in the calcitonin group. A statistically significant decrease occurred in the levels of sOC, uNTx and uZn after 3 and 6 months in patients receiving calcitonin therapy (P < 0.05). Levels of sOC and uNTx in calcitonin group were significantly different after 3 and 6 months from both placebo and baseline values of calcitonin group (P < 0.05). Levels of sOC, uNTx and uZn decreased about 40, 46 and 37%, respectively, in calcitonin group at 6 months after the start of treatment. Conclusions: Our study suggests that values of uNTx, uZn and sOC were significantly lower in the patient group than those in control group and in postmenopausal women with osteopororsis, calcitonin reduces the concentrations of uNTx, uZn and sOC. (c) 2004 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.maturitas.2004.07.013
dc.identifier.endpage253en_US
dc.identifier.issn0378-5122
dc.identifier.issn1873-4111
dc.identifier.issue3en_US
dc.identifier.pmid15978968
dc.identifier.scopus2-s2.0-20644461488
dc.identifier.scopusqualityQ1
dc.identifier.startpage246en_US
dc.identifier.urihttps://doi.org/10.1016/j.maturitas.2004.07.013
dc.identifier.urihttps://hdl.handle.net/11468/15802
dc.identifier.volume51en_US
dc.identifier.wosWOS:000230690400004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofMaturitas
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCalcitoninen_US
dc.subjectN-Telopeptideen_US
dc.subjectOsteocalcinen_US
dc.subjectOsteoporosisen_US
dc.subjectZinc Excretionen_US
dc.titleThe effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosisen_US
dc.titleThe effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu